Thymopentin is a synthetic pentapeptide which is the active site of the naturally occurring hormone thymopoietin with immunomodulating properties. Thymopentin can specifically promote the differentiation and maturation of thymic T cells and natural killer cells (NK) and enhance the function of T helper cells. thymic can achieve a two-way adjustment to the immune system by increasing the levels of intracellular cyclic adenosine monophosphate, elevating the activity of T cells, and regulating the proportions of T cell subsets. As an immunomodulating agent, Thymopentin is clinically used in the treatments of autoimmune diseases, such as e.g. atopic dermatitis, chronic lymphocytic leukemia, Sezary's syndrome, rheumatoid arthritis, as well as decreased immune competency in elder surgical patients. Due to poor membrane permeability, extensive metabolism in the GI, and extremely short half-life of 30 s, repeated injections or i.v infusions of Thymopentin are necessary which greatly restrict its clinical applications.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0030217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25576384 |
PubMed
Title | Date | PubMed |
---|---|---|
Effect of subcutaneous thymopentin treatment in drug addicts with persistent generalized lymphadenopathy. | 1987 Mar |
|
Zidovudine therapy of asymptomatic HIV1-infected patients and combined zidovudine-acyclovir therapy of HIV1-infected patients with oral hairy leukoplakia. | 1989 Apr |
|
Successful interferon alpha therapy in atopic dermatitis of Besnier's prurigo pattern with normal serum IgE and blood eosinophil fraction: randomized case-controlled study. | 2001 Jan 21 |
|
[Concentrations of MMP-1, TIMP-1, MMP-1/TIMP-1 and I CTP complexes in follicular fluid as related to fertilization rate in women treated with in-vitro fertilization]. | 2001 Mar |
|
[Stability evaluation of thymopentin in preparation process]. | 2003 Apr |
|
Analogs of RGDVY and GRGD peptides inhibit Mycobacterium kansasii phagocytosis. | 2003 Aug |
|
MS2Assign, automated assignment and nomenclature of tandem mass spectra of chemically crosslinked peptides. | 2003 Aug |
|
[Clinical trial to verify the value of the CD14(+) monocyte human leukocyte antigen DR as a marker in evaluating immunosuppression in patients with severe sepsis]. | 2003 Mar |
|
Quantitative analysis with desorption/ionization on silicon mass spectrometry using electrospray deposition. | 2003 Oct 15 |
|
[Controlled clinical study on 49 patients of SARS treated by integrative Chinese and Western medicine]. | 2003 Sep |
|
Trypsin-catalyzed kinetically controlled synthesis of a precursor dipeptide of thymopentin in organic solvents, using a free amino acid as nucleophile. | 2004 Feb |
|
Increased radiation toxicity by enhanced apoptotic clearance of HL-60 cells in the presence of the pentapeptide thymopentin, which selectively binds to apoptotic cells. | 2004 Mar 14 |
|
Chemical synthesis and application of C-terminally 5-carboxyfluorescein-labelled thymopentin as a fluorescent probe for thymopoietin receptor. | 2006 Dec |
|
Meta-analysis: the adjuvant role of thymopentin on immunological response to hepatitis B virus vaccine in end-stage renal disease. | 2006 Jun 1 |
|
Immunotherapy with canarypox vaccine and interleukin-2 for HIV-1 infection: termination of a randomized trial. | 2007 Jan 26 |
|
Thymic reticulo-epithelial cells: key cells of neuroendocrine regulation. | 2007 Jul |
|
[Research on thymopentin-loaded N-trimethyl chitosan nanoparticles administered through mouth]. | 2007 Sep |
|
Conjugation of thymopentin (TP5) with lipoamino acid residues increases the hydrolytic stability and preserves the biological activity. | 2007 Sep |
|
[Thymopentin 5 in treatment of relapse after extended thymectomy: a randomized comparative clinical trial of 135 patients with myasthenia gravis]. | 2008 Aug 26 |
|
Preparation and evaluation of poly-butylcyanoacrylate nanoparticles for oral delivery of thymopentin. | 2008 Jun |
|
Expression of thymosin alpha1-thymopentin fusion peptide in Pichia pastoris and its characterization. | 2008 Nov |
|
Characterization of a new inhalable thymopentin formulation. | 2009 Jun 22 |
|
[Immunomodulatory effects of thymopentin under acute and chronic inflammations in mice]. | 2009 Mar-Apr |
|
Recent advances in PEG-PLA block copolymer nanoparticles. | 2010 Nov 26 |
|
Preparation, characterization and in vivo pharmacodynamic evaluation of thymopentin loaded poly(lactide acid)/poly(lactide-co-glycolide acid) implants. | 2010 Oct 15 |
|
Preparation of gel-core-solid lipid nanoparticle: a novel way to improve the encapsulation of protein and peptide. | 2010 Sep |
Patents
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
89318-88-7
Created by
admin on Sat Dec 16 09:12:52 GMT 2023 , Edited by admin on Sat Dec 16 09:12:52 GMT 2023
|
PRIMARY | |||
|
53230082
Created by
admin on Sat Dec 16 09:12:52 GMT 2023 , Edited by admin on Sat Dec 16 09:12:52 GMT 2023
|
PRIMARY | |||
|
1938Y8P51M
Created by
admin on Sat Dec 16 09:12:52 GMT 2023 , Edited by admin on Sat Dec 16 09:12:52 GMT 2023
|
PRIMARY | |||
|
DTXSID80237615
Created by
admin on Sat Dec 16 09:12:52 GMT 2023 , Edited by admin on Sat Dec 16 09:12:52 GMT 2023
|
PRIMARY | |||
|
177966-81-3
Created by
admin on Sat Dec 16 09:12:52 GMT 2023 , Edited by admin on Sat Dec 16 09:12:52 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY |
ACTIVE MOIETY
SUBSTANCE RECORD